CClinicalTrials.gg
Sign In
Status unknownNCT05313126EXPOCAPUpdated Apr 6, 2022

Immuno-epidemiological and Socio-behavioral Evaluation of Release of Sterile Male Aedes Albopictus Mosquitoes on Human-vector Contacts

An interventional study of sterile insect technique (TIS) in Mosquito Bite, sponsored by Institut de Recherche pour le Developpement. Status unknown at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-06.

Sponsored by Institut de Recherche pour le Developpement · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial is based on 2 complementary components, named ExpAlbo Biomarker and CAPAlbo Questionnaire

  1. ExpAlbo Biomarker (Exposure to the Aedes albopictus mosquito): This component concerns the epidemiological evaluation of the effectiveness of the release of sterile male mosquitoes on the level of exposure of individuals to the bites of the tiger mosquito through the use of a new immunological biomarker of the human-vector contact, developed over the past 20 years by the IRD-MIVEGEC team. Indeed, when a person is bitten by a mosquito, he or she develops a defence reaction, called an immune reaction, against the mosquito's saliva. The main objective of this study is to measure this immune response, and more specifically the antibody response specifically directed against compounds (peptide = small fragment of a protein) in mosquito saliva, and to determine whether this anti-saliva antibody response, and therefore exposure to mosquito bites, decreases when the mosquito control strategy is applied.
  2. CAPAlbo Questionnaire: This component is concerned with assessing the impact of sterile male mosquito releases on perceptions and practices related to exposure to Aedes albopictus based on population-based questionnaire surveys. The main objective of these surveys is to determine whether changes in objective exposure to Aedes albopictus mosquitoes are associated with changes in the perception of the nuisance and in the lifestyle habits of respondents, particularly those related to the prevention of mosquito bites (such as the use of repellents or mosquito nets).
02

Conditions studied

  • Mosquito Bite

Browse trials for

03

In context

Infertility

2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.

This study's planned enrollment of 500 is above the median of 120 across 1,698 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Institut de Recherche pour le Developpement is the lead sponsor of 49 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • To inhabit on a regular basis in the intervention/control area
  • To speak French
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    sterile male Aedes albopictus-exposed

    Sterile male Aedes albopictus are released in the area.

    Other: sterile insect technique (TIS)

  • No intervention
    control

    Sterile male Aedes albopictus are not released in the area.

Interventions

  • Othersterile insect technique (TIS)

    Sterile male Aedes albopictus mosquitos are released in the area/neighborhood

06

What researchers measure

Primary outcomes

  1. Immunological indicators

    Biomarker based on the measurement of human IgG antibody levels specific to one peptide of Aedes saliva (i.e. Nterm-24kDa salivary peptide)

    Time frame: 6 months

  2. Immunological indicators

    Biomarker based on the measurement of human IgG antibody levels specific to one peptide of Aedes saliva (i.e. Nterm-24kDa salivary peptide)

    Time frame: 12 months

  3. Exposure to Aedes mosquito

    self-perceived exposure to mosquito will be assessed by questionnaire

    Time frame: 6 months

  4. Exposure to Aedes mosquito

    self-perceived exposure to mosquito will be assessed by questionnaire

    Time frame: 12 months

Secondary outcomes

  1. Protective behavior

    a composite indicator derived from a questionnaire will rate the protective behavior of the participants to avoid mosquito bites

    Time frame: 6 months

  2. Protective behavior

    a composite indicator derived from a questionnaire will rate the protective behavior of the participants to avoid mosquito bites

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • population générale (quartier Duparc (Sainte Marie) et Quartier Bois rouge)
    La Réunion, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05313126
Lead sponsor
Institut de Recherche pour le Developpement
Responsible party
Sponsor
First posted
Apr 6, 2022
Start date
Nov 9, 2021
Primary completion
Jun 2023 (estimated)
Completion
Jun 2023 (estimated)
Last update
Apr 6, 2022

Study contacts

Franck Remoué, PhD
Contact
franck.remoue@ird.fr
+33 (0)4 67 41 61 30
Jocelyn Raude, PhD
Contact
jocelyn.raude@ehesp.fr
+33 (0)2 99 02 26 15

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Infertility→

Other studies from this sponsor

Institut de Recherche pour le Developpement

Start the discussion